



Published in final edited form as:

*J Cell Physiol.* 2014 November ; 229(11): 1736–1743. doi:10.1002/jcp.24625.

## NEMO-LIKE KINASE REGULATES POSTNATAL SKELETAL HOMEOSTASIS

Ernesto Canalis<sup>1,2,\*</sup>, Lauren Kranz<sup>1</sup>, and Stefano Zanotti<sup>1,2</sup>

<sup>1</sup>Department of Research Saint Francis Hospital and Medical Center, Hartford, CT, 06105

<sup>2</sup>The University of Connecticut School of Medicine, Farmington, CT, 06030

### Abstract

Nemo-like kinase (Nlk) is related to the mitogen-activated protein (MAP) kinases and known to regulate signaling pathways involved in osteoblastogenesis. *In vitro* Nlk suppresses osteoblastogenesis, but the consequences of the *Nlk* inactivation in the skeleton *in vivo* are unknown. To study the function of Nlk, *Nlk<sup>loxP/loxP</sup>* mice, where the *Nlk* exon2 is flanked by *loxP* sequences, were mated with mice expressing the Cre recombinase under the control of the paired-related homeobox gene 1 (*Prx1*) enhancer (*Prx1-Cre*), the Osterix (*Osx-Cre*) or the osteocalcin/ bone gamma carboxyglutamate protein (*Bglap-Cre*) promoter. *Prx1-Cre;Nlk<sup>+/+</sup>* mice did not exhibit a skeletal phenotype except for a modest increase in trabecular number and connectivity observed only in 3 month old male mice. *Osx-Cre;Nlk<sup>+/+</sup>* male and female mice exhibited an increase in trabecular bone volume secondary to an increased trabecular number at 3 months of age. Bone histomorphometry revealed a decrease in osteoclast number and eroded surface in male mice, and decreased osteoblast number and function in female mice. Expression of osteoprotegerin mRNA was increased in calvarial extracts, explaining the decreased osteoclast and osteoblast number. The conditional deletion of *Nlk* in mature osteoblasts (*Bglap-Cre;Nlk<sup>+/+</sup>*) resulted in no skeletal phenotype in 1 to 6 month old male or female mice. In conclusion, when expressed in undifferentiated osteoblasts, Nlk is a negative regulator of skeletal homeostasis possibly by targeting signals that regulate osteoclastogenesis and bone resorption.

### Keywords

Nemo-like kinase; MAP kinases; bone remodeling; skeletal homeostasis; Notch

## INTRODUCTION

The fate of mesenchymal cells and their differentiation toward cells of the osteoblastic lineage is tightly controlled by extracellular and intracellular signals. Some, such as bone morphogenetic proteins (BMPs) and Wnt, favor osteoblastogenesis (Canalis et al, 2003;Gazzerro and Canalis, 2006;Canalis, 2013;Monroe et al, 2012). Other signals, such as Notch, impair the differentiation of cells of the osteoblastic lineage (Deregowski et al,

\*Address correspondence to: Ernesto Canalis, M.D., Department of Research, Saint Francis Hospital and Medical Center, 114 Woodland Street, Hartford, CT 06105-1299, Tel: (860)714-4068, Fax: (860)714-8053, ecanalis@stfranciscare.org.

**Disclosure of potential conflict of interests:** The authors declare that there are no conflicts of interest.

2006;Zanotti and Canalis, 2010;Canalis et al, 2013;Zanotti and Canalis, 2013). The activity of these factors is tightly controlled by extracellular proteins that bind to the agent or to its receptors, and by intracellular proteins and regulatory kinases.

Nemo-like kinase (Nlk) is an evolutionary conserved kinase that phosphorylates serine or threonine residues immediately preceding a proline residue (Harada et al, 2002;Ishitani and Ishitani, 2013). Nlk is structurally related to mitogen activated protein (MAP) kinases and is ~42% identical to extracellular signal regulated kinase (ERK)2 (Brott et al, 1998). Recently, Nlk was found to play a critical role in the regulation of diverse signaling pathways, in particular the Wnt/ $\beta$ -catenin, BMP/Smad and the Notch signaling pathways (Ishitani et al, 2003;Ishitani et al, 2010;Zeng et al, 2007). Nlk phosphorylates T cell factor (TCF) and lymphoid enhancer factor (LEF) preventing TCF/LEF binding to DNA and gene transcription (Ishitani et al, 2003). As a consequence, Nlk downregulates the canonical Wnt/ $\beta$ -catenin signaling pathway acting as an intracellular Wnt antagonist. In addition, Nlk interacts and phosphorylates  $\beta$ -catenin in *Drosophila*, although it is not known whether this mechanism operates in mammalian cells (Mirkovic et al, 2011). Nlk phosphorylates Smad4 antagonizing BMP signaling (Shi et al, 2010;Zeng et al, 2007). In addition, the Notch intracellular domain (NICD) is a substrate of Nlk, and the phosphorylation of NICD impairs the formation of a Notch transcriptional complex and decreases canonical Notch signaling (Ishitani et al, 2010). Because BMP, Wnt and Notch play fundamental roles in osteoblastogenesis and osteoclastogenesis, Nlk has the potential to affect both processes of bone remodeling.

Nlk is expressed by calvarial osteoblasts, and forced expression of Nlk in ST-2 stromal cells and osteoblasts using retroviral vectors inhibits osteoblastic differentiation (Nifuji et al, 2010). Furthermore, we demonstrated that downregulation of Nlk enhanced osteoblastogenesis by augmenting BMP-2/Smad signaling and Wnt/ $\beta$ -catenin signaling (Zanotti and Canalis, 2012). However, the function of Nlk in the skeleton *in vivo* has not been defined. The targeted global disruption of *Nlk* in C57BL/6 mice causes embryonic lethality, although its disruption in 129SvJ/C57BL/6 mice leads to survival for up to 4 – 6 weeks (Kortenjann et al, 2001). These *Nlk* mutants exhibit a hematopoietic cell phenotype, decreased bone lining cells and increased bone marrow adipocytes, but a skeletal phenotype was not explored or reported (Kortenjann et al, 2001). The increased adipocytes are explained by an inhibitory effect of Nlk on adipogenesis secondary to a suppression of the transactivation of peroxisome proliferator-activated receptor (PPAR)  $\gamma$  (Takada et al, 2007). Since mesenchymal cells have the potential to differentiate into adipocytes and osteoblasts, this may serve as an additional regulatory control determined by Nlk (Pereira et al, 2002).

The intent of the present study was to define the function of Nlk in skeletal tissue *in vivo*. For this purpose, we created *Nlk*<sup>loxP/loxP</sup> conditional mice. *Nlk* was inactivated by Cre recombination directed by either the paired-related homeobox gene 1 (*Prx1*) enhancer expressed in limb buds at day 10.5 of embryonic life (E10.5), the osterix (*Osx*) promoter expressed in osteoblast precursors or the osteocalcin/bone gamma carboxyglutamate protein (*Bglap*) promoter expressed in mature osteoblasts (Logan et al, 2002;Rodda and McMahon, 2006;Zhang et al, 2002). The skeletal phenotype of *Nlk* conditional null mice was determined by microcomputed tomography and by histomorphometric analysis.

## MATERIALS AND METHODS

### Generation of *Nlk* Null Mice

To generate a conditional allele of *Nlk*, approximately 10 kilobases (kb) of *Nlk* sequence containing exon 2 were selected from a bacterial artificial chromosome library of C57BL/6 mouse genomic DNA (id RP24-223B7), and retrieved into a PL253 vector. The vector contains an MC1 driven herpes simplex virus-thymidine kinase (MC1-HSV-TK) cassette for negative selection of embryonic stem (ES) cells (Liu et al, 2003; Mansour et al, 1988). A 5' *loxP* site was introduced approximately 1.1 kb 5' of exon 2, followed by the insertion of a phosphoglycerate kinase promoter-driven neomycin (neo) selection cassette flanked by flippase recognition target (*Frt*) sites and a 3' *loxP* site (*Frt-PGKneo-Frt-LoxP*) approximately 500 bp 3' of exon 2 (Figure 1A) (Buchholz et al, 1996). The targeting vector containing 5.5 kb of 5' homology arm and 3.1 kb of 3' homology arm was linearized by *NotI* digestion, and electroporated into ES cells derived from F1 (129Svj/C57BL/6) embryos. G418 and gancyclovir resistant colonies were selected and screened by long range nested polymerase chain reaction (PCR) using primers specific to the *loxP* sites and primers outside the 5' and 3' homology arms (Lay et al, 1998). Targeted ES clones were expanded and confirmed by long range PCR and used for aggregations to generate chimeric mice at the Gene Targeting and Transgenic Facility of the University of Connecticut Health Center (Farmington, CT). Chimeras were bred with mice expressing the Flp recombinase under the control of the *Gt(ROSA)26Sor* promoter (Jax Stock 003946; Jackson Laboratory, Bar Harbor, ME) for the removal of the *PGKneo* selection cassette, as previously reported (Canalis et al, 2010a; Canalis et al, 2010b; Farley et al, 2000). The excision of the selection cassette was confirmed by PCR, and the resulting *Flp* recombinase transgene was segregated by mating the mice with C57BL/6 wild type mice. Cre recombination mediates excision of exon 2, partially encoding for the kinase domain, and causes a frameshift so that the transcript is truncated upstream the kinase domain.

As an initial step in the inactivation of *Nlk*, heterozygous transgenics expressing the Cre recombinase under the control of the *Prx1* enhancer (Jackson Laboratory, Bar Harbor, ME), the osteocalcin or *Bglap* (T. Clemens, Baltimore, MD) or the osterix (*Osx*) (Jackson Laboratory) promoter were mated with *Nlk<sup>loxP/loxP</sup>* to create *Prx1-Cre<sup>+/-</sup>;Nlk<sup>loxP/loxP</sup>*, *Bglap-Cre<sup>+/-</sup>;Nlk<sup>loxP/loxP</sup>* and *Osx-Cre<sup>+/-</sup>;Nlk<sup>loxP/loxP</sup>* mice (Logan et al, 2002; Rodda and McMahon, 2006; Zhang et al, 2002). These were mated with *Nlk<sup>loxP/loxP</sup>* mice to generate an experimental cohort in which *Nlk* exon 2 is deleted by Cre in the limb bud (*Prx1-Cre;Nlk<sup>loxP/loxP</sup>*), and in mature (*Bglap-Cre;Nlk<sup>loxP/loxP</sup>*) or immature (*Osx-Cre;Nlk<sup>loxP/loxP</sup>*) osteoblasts and to generate control littermates without Cre-mediated inactivation (*Nlk<sup>loxP/loxP</sup>*). *Prx1-Cre*, *Bglap-Cre* and *Osx-Cre* transgenics were maintained in a C57BL/6 background and *Nlk<sup>loxP/loxP</sup>* in a 129SvJ/C57BL/6 background. Because in *Osx-Cre* transgenics the expression of Cre is under the control of the tet-off cassette, pregnant dams were treated with a diet containing 625 mg of doxycycline hyclate/kg of chow to deliver 2–3 mg of doxycycline daily from the time of conception to delivery (Harlan Laboratories, Indianapolis, IN).

Genotyping of *Prx1-Cre*, *Bglap-Cre*, *Osx-Cre*, *Nik<sup>loxP</sup>* and *Nik<sup>WT</sup>* alleles was carried out by PCR in tail DNA extracts (Table 1A). Deletion of the *neo* cassette in *Nik<sup>loxP</sup>* mice by Flp recombination was determined by PCR in tail DNA and deletion of *loxP* flanked sequences in *Nik<sup>loxP/loxP</sup>* mice by Cre recombination was documented by PCR in DNA extracted from calvariae (Figure 1B). All animal experiments were approved by the Animal Care and Use Committee of Saint Francis Hospital and Medical Center.

### Skeletal Staining

To assess the effect of *Nik* on skeletal development, skeletons from newborns were fixed with ethanol. Cartilage was stained with Alcian blue and mineralized bone with alizarin red, followed by the addition of 1% potassium hydroxide to remove adjacent tissues, as described (O'Brien et al, 1996).

### Microcomputed Tomography ( $\mu$ CT)

Bone microarchitecture of femurs from experimental and control mice was determined using a microcomputed tomography instrument ( $\mu$ CT 40; Scanco Medical AG, Bassersdorf, Switzerland), which was calibrated weekly using a phantom provided by the manufacturer (Bouxsein et al, 2010; Glatt et al, 2007). Femurs were scanned in 70% ethanol at high resolution, energy level of 55 kVp, intensity of 145  $\mu$ A and integration time of 200 ms. A total of 100 slices at midshaft and 160 slices at the distal metaphysis were acquired at an isotropic voxel dimension of 6  $\mu$ m or 216  $\mu$ m<sup>3</sup> and a slice thickness of 6  $\mu$ m, and chosen for analysis. Trabecular bone volume fraction and microarchitecture were evaluated starting approximately 1.0 mm proximal from the femoral condyles. Contours were manually drawn every 10 slices a few voxels away from the endocortical boundary to define the region of interest for analysis. The remaining slice contours were iterated automatically. Trabecular regions were assessed for total volume, bone volume, bone volume fraction (bone volume/total volume, BV/TV), trabecular thickness, trabecular number, trabecular separation, connectivity density and structure model index (SMI), using a Gaussian filter ( $\sigma = 0.8$ ) and user defined thresholds (Bouxsein et al, 2010). For analysis of femoral cortical bone, contours were iterated across 100 slices along the cortical shell of the femoral midshaft, excluding the marrow cavity. Analysis of BV/TV, porosity, cortical thickness, total cross sectional and cortical bone area, periosteal and endocortical perimeter and material density were performed using a Gaussian filter ( $\sigma = 0.8$ ) and user defined thresholds. The terminology and units used are those recommended by a committee established by the Journal of Bone and Mineral Research (Bouxsein et al, 2010).

### Bone Histomorphometry

Static and dynamic histomorphometry was carried out on experimental and control mice after they were injected with calcein, 20 mg/kg, and demeclocycline, 50 mg/kg, at an interval of 5 days. Five  $\mu$ m longitudinal sections of femurs and cross sections at the mid-femoral diaphysis were cut on a microtome (Microm, Richards-Allan Scientific, Kalamazoo, MI), and stained with 0.1% toluidine blue. Static parameters of bone formation and resorption were measured in a defined area between 360  $\mu$ m and 2160  $\mu$ m from the growth plate, using an OsteoMeasure morphometry system (Osteometrics, Atlanta, GA). For

dynamic histomorphometry, mineralizing surface per bone surface and mineral apposition rate were measured on unstained sections under ultraviolet light using a triple diamidino-2-phenylindole/fluorescein/Texas red set long pass filter, and bone formation was calculated. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society of Bone and Mineral Research (Dempster et al, 2013;Parfitt et al, 1987).

### Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted from calvariae and mRNA levels determined by qRT-PCR (Nazarenko et al, 2002a;Nazarenko et al, 2002b). For this purpose, equal amounts of RNA were reverse-transcribed using iScript RT-PCR kit (BioRad, Hercules, CA), according to manufacturer's instructions, and amplified in the presence of specific primers (Table 1B), and iQ SYBR Green Supermix (BioRad) at 60°C for 45 cycles. Transcript copy number was estimated by comparison with a serial dilution of cDNA for *Nlk* and *Tnfrsf11b*, encoding for Osteoprotegerin (Opg), both from American Type Tissue Culture Collection (ATCC; Manassas, VA), and *Tnfsf11*, encoding for Receptor activated of nuclear factor-kappa B ligand (Rankl) (BioSciences, Nottingham, UK). Reactions were conducted in a CFX96 qRT-PCR detection system (BioRad), and fluorescence was monitored during every PCR cycle at the annealing step. Data are expressed relative to ribosomal protein L38 (*Rpl38*) copy number, estimated by comparison with a serial dilution of cDNA for *Rpl38* (ATCC).

### Serum Osteoprotegerin

Murine Opg was measured by enzyme-linked immune-absorbent assay in serum from *Osx-Cre;Nlk<sup>-/-</sup>* and control mice using a commercially available kit in accordance with manufacturer's instructions (R and D Systems, Minneapolis, MN).

### Statistical Analysis

Data are expressed as means  $\pm$  SEM. Statistical differences were determined by unpaired Student's *t*-test or ANOVA.

## RESULTS

### Conditional Inactivation of *Nlk* During Development

To induce the conditional inactivation of *Nlk* in the limb bud, *Prx1-Cre<sup>+/-</sup>;Nlk<sup>loxP/loxP</sup>* mice were mated with *Nlk<sup>loxP/loxP</sup>* mice to create limb bud specific *Prx1-Cre;Nlk<sup>-/-</sup>* conditional null and *Nlk<sup>loxP/loxP</sup>* littermate controls (Logan et al, 2002). *Prx1-Cre;Nlk<sup>-/-</sup>* mice appeared normal and not different from wild type littermate controls. Alizarin red and alcian blue staining of the skeleton of newborn mice did not reveal apparent differences between *Prx1-Cre;Nlk<sup>-/-</sup>* and control mice. At 1 and 3 months of age, the weight (not shown) and femoral length (Table 2) of *Prx1-Cre;Nlk<sup>-/-</sup>* mice were not significantly different from controls.  $\mu$ CT revealed no differences between *Prx1-Cre;Nlk<sup>-/-</sup>* and control mice at 1 month of age and only minor differences at 3 months of age, where *Prx1-Cre;Nlk<sup>-/-</sup>* mice exhibited a ~15% increase in trabecular number and a ~75% increase in connectivity (Table 2).

### Conditional Inactivation of *Nlk* in Osteoblast Precursors

For the conditional inactivation of *Nlk* in osteoblast precursors, *Osx-Cre<sup>+/-</sup>;Nlk<sup>loxP/loxP</sup>* mice were crossed with *Nlk<sup>loxP/loxP</sup>* mice to create *Osx-Cre;Nlk<sup>-/-</sup>* experimental and *Nlk<sup>loxP/loxP</sup>* controls. *Osx-Cre;Nlk<sup>-/-</sup>* mice appeared normal. Except for an unexplained 15% decrease in the weight of 6 month old female *Osx-Cre;Nlk<sup>-/-</sup>* mice, the weight (not shown) and femoral length (Table 3) of experimental null mice were not different from littermate controls.  $\mu$ CT did not reveal a skeletal phenotype in 1 month old *Osx-Cre;Nlk<sup>-/-</sup>* mice of either sex (Table 3). In contrast, at 3 months of age *Osx-Cre;Nlk<sup>-/-</sup>* of both sexes exhibited a 1.5 to 1.8 fold increase in cancellous bone volume, secondary to an increase in trabecular number (Table 3, Figure 2). Connectivity density was increased by >2 fold, and SMI revealed a predominance of plate-like trabeculae. Minor changes in cortical microarchitecture, such as a ~10% decrease in cortical thickness, were observed in 3 month old female, but not in male, mice. The skeletal phenotype was transient and  $\mu$ CT revealed that the skeletal microarchitecture of 6 month old *Osx-Cre;Nlk<sup>-/-</sup>* mice of both sexes was not different from controls, other than a modest decrease in trabecular thickness in male mice. Histomorphometric analysis of *Osx-Cre;Nlk<sup>-/-</sup>* male 3 month old mice confirmed an increase in trabecular bone volume, albeit not statistically significant, and a decrease in the number of osteoclasts and in eroded surface, explaining the skeletal phenotype detected by  $\mu$ CT (Table 4). Three month old female *Osx-Cre;Nlk<sup>-/-</sup>* mice exhibited an increase in trabecular bone volume, and a decrease in the number of osteoblasts but no changes in osteoclast number, or in parameters of bone resorption or dynamic parameters of bone formation (Table 4). However, osteoid surface/bone surface was decreased in female and male mice. Bone marrow adipocyte number was not changed in *Osx-Cre;Nlk<sup>-/-</sup>* mice of either sex.

To determine possible mechanisms responsible for the phenotype observed, calvariae from *Osx-Cre;Nlk<sup>-/-</sup>* and control mice were extracted and analyzed for changes in mRNA expression. The *Nlk* inactivation resulted in a ~2 fold increase in *Opg* mRNA expression without a significant change in *Rankl* mRNA, explaining the suppression of bone resorption (Figure 3). Immunoreactive serum *Opg* was not different between *Osx-Cre;Nlk<sup>-/-</sup>* and control mice of either sex at 1 month (not shown) or 3 months of age. Serum *Opg* in 3 month old male control mice was (means  $\pm$  SEM; n = 3 – 5)  $3.6 \pm 0.1$  and in *Osx-Cre;Nlk<sup>-/-</sup>* was  $3.5 \pm 0.4$   $\mu$ g/L; serum *Opg* in female control mice was  $4.3 \pm 0.2$  and in *Osx-Cre;Nlk<sup>-/-</sup>* was  $4.5 \pm 0.2$   $\mu$ g/L. This suggests that *Opg* acted locally in the bone microenvironment, and not systemically.

### Conditional Inactivation of *Nlk* in Mature Osteoblasts

For the conditional deletion of *Nlk* in mature osteoblasts, *Bglap-Cre<sup>+/-</sup>;Nlk<sup>loxP/loxP</sup>* were mated with *Nlk<sup>loxP/loxP</sup>* mice to create *Bglap-Cre;Nlk<sup>-/-</sup>* as an experimental group and *Nlk<sup>loxP/loxP</sup>* as littermate controls. *Bglap-Cre;Nlk<sup>-/-</sup>* conditional null mice appeared visually normal, had normal weight (not shown) and their femoral length was not affected (Table 5).  $\mu$ CT of trabecular and cortical bone of 1, 3 and 6 month old mice of both sexes did not reveal any differences between *Bglap-Cre;Nlk<sup>-/-</sup>* mice and littermate controls, indicating that *Nlk* is dispensable for the function of mature osteoblasts (Table 5).

## DISCUSSION

Our findings demonstrate that the conditional inactivation of *Nlk* in *Osx*-expressing cells results in an increase in bone volume indicating that Nlk has a negative effect on bone homeostasis when expressed in undifferentiated cells of the osteoblastic lineage. In contrast, the conditional inactivation of *Nlk* in the limb bud or in mature osteoblasts, achieved by crossing *Nlk* conditional mice with transgenics expressing the Cre recombinase under the control of either the *Prx1* enhancer or the *Bglap* or *Osteocalcin* promoter, did not cause an obvious skeletal phenotype. This would indicate that Nlk is dispensable for skeletal development or for the function of mature osteoblasts, but that it plays an important role in osteoblastogenesis and in the function of undifferentiated cells of the osteoblastic lineage. These findings are consistent with previous *in vitro* work demonstrating that Nlk modifies the activity of signaling molecules required for osteoblastic differentiation that target undifferentiated cells of the osteoblastic lineage (Zanotti and Canalis, 2012). It is also possible that the expression of MAP kinases by mature osteoblasts prevented the *Nlk* inactivation from affecting osteoblast function (Franceschi et al, 2007). The microarchitectural skeletal phenotype caused by the conditional *Nlk* inactivation in osteoblast precursors was not sexually dimorphic and was observed in male and female mice. However, it appeared to be somewhat more pronounced in male mice and it affected primarily cancellous and to a minor extent cortical bone. The phenotype was observed at 3 months of age, and not in older animals, possibly because *Osx* expressing cells differentiate into mature osteoblasts and osteocytes, a population of cells not influenced by *Nlk* inactivation (Liu et al, 2013;Maes et al, 2010). *Osx-Cre;Nlk*<sup>-/-</sup> mice did not manifest a phenotype at 1 month of age, possibly because pregnant dams were treated with doxycycline preventing Cre activation during gestation, and in the progeny perinatally and at an early age.

The mechanism responsible for the increase in cancellous bone in male *Osx-Cre;Nlk*<sup>-/-</sup> mice appeared to be a decrease in osteoclast number and an inhibition of bone resorption. However, the mechanism responsible for the increased bone volume in female mice was less clear. Indeed, a decrease in osteoblast number and osteoid surface was noted in female *Osx-Cre;Nlk*<sup>-/-</sup> mice as well as a non-significant ~15% decrease in osteoclast number and eroded surface. It is possible that Nlk targets signals that suppress osteoclastogenesis and osteoblastogenesis, and its downregulation results in an enhanced activity of these inhibitory pathways. The inactivation of *Nlk* caused an inhibition of bone resorption, and the effect appeared related to an increase in the expression of Opg mRNA in bone extracts. Although Nlk is required for the induction of Opg following cellular mechanical loading, its downregulation did not preclude the induction of Opg mRNA (Yu et al, 2010). However, serum Opg levels were not affected suggesting that the impact of Nlk on Opg was limited to an effect within the skeletal microenvironment.

The mechanism of action of Nlk *in vitro* entails the inhibition of BMP-2 and Wnt signaling, but these mechanisms do not seem to explain the phenotype observed *in vivo*, since the *Nlk* inactivation did not result in increased osteoblast number or bone formation, as it would be expected from enhanced BMP or Wnt signaling (Canalis et al, 2003;Canalis, 2013;Zanotti and Canalis, 2012). If enhanced BMP and Wnt activity occurred, this could have been

modest or transient. Nlk targets the Notch receptor, decreasing Notch signaling, and the inactivation of *Nlk* in osteoblast precursors could have caused enhanced Notch signaling explaining the phenotype observed in *Osx-Cre;Nlk*<sup>-/-</sup> since Notch suppresses osteoclastogenesis and increases *Opg* expression (Bai et al, 2008;Hilton et al, 2008;Zanotti and Canalis, 2010). Enhanced Notch signaling may explain the decrease in osteoblast number observed in female mice, since Notch is an inhibitor of osteoblastic differentiation and function (Zanotti and Canalis, 2010;Zanotti and Canalis, 2013;Engin et al, 2008). However, changes in Notch signaling are of short duration and difficult to verify in *in vivo* models.

Nlk prevents the commitment of mesenchymal stem cells to the adipocytic lineage by modifying chromatin organization and suppressing PPAR- $\gamma$  transactivation (Takada et al, 2007). Recent work has demonstrated that *Osx*-labeled cells generate various bone marrow stromal cells including adipocytes (Liu et al, 2013). However, adipocyte number was not affected in *Osx-Cre;Nlk*<sup>-/-</sup> mice suggesting that adipocyte precursors were not targeted by *Osx* or that Nlk did not affect adipogenesis under the experimental conditions of this study.

In conclusion, our studies reveal that in osteoblast precursors Nlk has a negative effect on bone homeostasis, increasing bone resorption and decreasing cancellous bone volume, possibly by regulating selected signaling pathways in the skeleton.

## Acknowledgments

National Institute of Arthritis and Musculoskeletal and Skin Diseases; AR063049 and National Institute of Diabetes and Digestive and Kidney Diseases; DK045227.

The authors thank T. Clemens for *Bglap-Cre* transgenics; Alison Kent and David Bridgewater for technical assistance, Mary Yurczak for secretarial help and Siu-Pok Yee for helpful discussions.

## ABBREVIATIONS

<b>Bglap</b>	bone gamma carboxyglutamate protein
<b>BMP</b>	bone morphogenetic protein
<b>ERK</b>	extracellular signal regulated kinase
<b>ES</b>	embryonic stem
<b>FRT</b>	Flp recognition target
<b>Id1</b>	Inhibitor of DNA binding
<b>kb</b>	kilobase
<b>LEF</b>	lymphoid enhancer factor
<b><math>\mu</math>CT</b>	microcomputed tomography
<b>MAP</b>	mitogen-activated protein
<b>neo</b>	neomycin
<b>Nlk</b>	Nemo-like kinase




<b>NICD</b>	Notch intracellular domain
<b>Opg</b>	Osteoprotegerin
<b>Osx</b>	osterix
<b>PCR</b>	polymerase chain reaction
<b>PPAR<math>\gamma</math></b>	peroxisome proliferator-activated receptor $\gamma$
<b>qRT-PCR</b>	quantitative reverse transcription-polymerase chain reaction
<b>Prx</b>	paired-related homeobox gene
<b>Rankl</b>	Receptor activated of nuclear factor-kappa B ligand
<b>Rpl38</b>	ribosomal protein L38
<b>SMI</b>	structure model index
<b>TCF</b>	T cell factor

## LITERATURE CITED


- Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. *J Biol Chem.* 2008; 283:6509–6518. [PubMed: 18156632]
- Bouxein ML, Boyd SK, Christiansen BA, Goldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res.* 2010; 25:1468–1486. [PubMed: 20533309]
- Brott BK, Pinsky BA, Erikson RL. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. *Proc Natl Acad Sci U S A.* 1998; 95:963–968. [PubMed: 9448268]
- Buchholz F, Ringrose L, Angrand PO, Rossi F, Stewart AF. Different thermostabilities of FLP and Cre recombinases: implications for applied site-specific recombination. *Nucleic Acids Res.* 1996; 24:4256–4262. [PubMed: 8932381]
- Canalis E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. *Nat Rev Endocrinol.* 2013; 9:575–583. [PubMed: 23938284]
- Canalis E, Economides AN, Gaggero E. Bone morphogenetic proteins, their antagonists, and the skeleton. *Endocr Rev.* 2003; 24:218–235. [PubMed: 12700180]
- Canalis E, Parker K, Feng JQ, Zanotti S. Osteoblast Lineage-specific Effects of Notch Activation in the Skeleton. *Endocrinology.* 2013; 154:623–634. [PubMed: 23275471]
- Canalis E, Smerdel-Ramoya A, Durant D, Economides AN, Beamer WG, Zanotti S. Nephroblastoma Overexpressed (NOV) Inactivation Sensitizes Osteoblasts To Bone Morphogenetic Protein-2 But NOV Is Dispensable For Skeletal Homeostasis. *Endocrinology.* 2010a; 151:221–233. [PubMed: 19934377]
- Canalis E, Zanotti S, Beamer WG, Economides AN, Smerdel-Ramoya A. Connective Tissue Growth Factor Is Required for Skeletal Development and Postnatal Skeletal Homeostasis in Male Mice. *Endocrinology.* 2010b; 151:3490–3501. [PubMed: 20534727]
- Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res.* 2013; 28:2–17. [PubMed: 23197339]
- Deregowski V, Gaggero E, Priest L, Rydzziel S, Canalis E. Notch 1 Overexpression Inhibits Osteoblastogenesis by Suppressing Wnt/beta-Catenin but Not Bone Morphogenetic Protein Signaling. *J Biol Chem.* 2006; 281:6203–6210. [PubMed: 16407293]

- Engin F, Yao Z, Yang T, Zhou G, Bertin T, Jiang MM, Chen Y, Wang L, Zheng H, Sutton RE, Boyce BF, Lee B. Dimorphic effects of Notch signaling in bone homeostasis. *Nat Med.* 2008; 14:299–305. [PubMed: 18297084]
- Farley FW, Soriano P, Steffen LS, Dymecki SM. Widespread recombinase expression using FLP<sub>eR</sub> (flipper) mice. *Genesis.* 2000; 28:106–110. [PubMed: 11105051]
- Franceschi RT, Ge C, Xiao G, Roca H, Jiang D. Transcriptional regulation of osteoblasts. *Ann N Y Acad Sci.* 2007; 1116:196–207. [PubMed: 18083928]
- Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. *Rev Endocr Metab Disord.* 2006; 7:51–65. [PubMed: 17029022]
- Glatt V, Canalis E, Stadmeier L, Bouxsein ML. Age-Related Changes in Trabecular Architecture Differ in Female and Male C57BL/6J Mice. *J Bone Miner Res.* 2007; 22:1197–1207. [PubMed: 17488199]
- Harada H, Yoshida S, Nobe Y, Ezura Y, Atake T, Koguchi T, Emi M. Genomic structure of the human NLK (nemo-like kinase) gene and analysis of its promoter region. *Gene.* 2002; 285:175–182. [PubMed: 12039044]
- Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. *Nat Med.* 2008; 14:306–314. [PubMed: 18297083]
- Ishitani T, Hirao T, Suzuki M, Isoda M, Ishitani S, Harigaya K, Kitagawa M, Matsumoto K, Itoh M. Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. *Nat Cell Biol.* 2010; 12:278–285. [PubMed: 20118921]
- Ishitani T, Ishitani S. Nemo-like kinase, a multifaceted cell signaling regulator. *Cell Signal.* 2013; 25:190–197. [PubMed: 23000342]
- Ishitani T, Ninomiya-Tsuji J, Matsumoto K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/ beta-catenin signaling. *Mol Cell Biol.* 2003; 23:1379–1389. [PubMed: 12556497]
- Kortenjann M, Nehls M, Smith AJ, Carsetti R, Schuler J, Kohler G, Boehm T. Abnormal bone marrow stroma in mice deficient for nemo-like kinase, *Nlk*. *Eur J Immunol.* 2001; 31:3580–3587. [PubMed: 11745377]
- Lay JM, Friis-Hansen L, Gillespie PJ, Samuelson LC. Rapid confirmation of gene targeting in embryonic stem cells using two long-range PCR techniques. *Transgenic Res.* 1998; 7:135–140. [PubMed: 9608741]
- Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. *Genome Res.* 2003; 13:476–484. [PubMed: 12618378]
- Liu Y, Strecker S, Wang L, Kronenberg MS, Wang W, Rowe DW, Maye P. Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. *PLoS One.* 2013; 8:e71318. [PubMed: 23951132]
- Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. Expression of Cre Recombinase in the developing mouse limb bud driven by a *Prxl* enhancer. *Genesis.* 2002; 33:77–80. [PubMed: 12112875]
- Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, Carmeliet G, Kronenberg HM. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. *Dev Cell.* 2010; 19:329–344. [PubMed: 20708594]
- Mansour SL, Thomas KR, Capecchi MR. Disruption of the proto-oncogene *int-2* in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. *Nature.* 1988; 336:348–352. [PubMed: 3194019]
- Mirkovic I, Gault WJ, Rahnama M, Jenny A, Gaengel K, Bessette D, Gottardi CJ, Verheyen EM, Mlodzik M. Nemo kinase phosphorylates beta-catenin to promote ommatidial rotation and connects core PCP factors to E-cadherin-beta-catenin. *Nat Struct Mol Biol.* 2011; 18:665–672. [PubMed: 21552260]
- Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. *Gene.* 2012; 492:1–18. [PubMed: 22079544]


- Nazarenko I, Lowe B, Darfler M, Ikonomi P, Schuster D, Rashtchian A. Multiplex quantitative PCR using self-quenched primers labeled with a single fluorophore. *Nucleic Acids Res.* 2002a; 30:e37. [PubMed: 11972352]
- Nazarenko I, Pires R, Lowe B, Obaidy M, Rashtchian A. Effect of primary and secondary structure of oligodeoxyribonucleotides on the fluorescent properties of conjugated dyes. *Nucleic Acids Res.* 2002b; 30:2089–2195. [PubMed: 11972350]
- Nifuji A, Ideno H, Ohyama Y, Takanabe R, Araki R, Abe M, Noda M, Shibuya H. Nemo-like kinase (NLK) expression in osteoblastic cells and suppression of osteoblastic differentiation. *Exp Cell Res.* 2010; 316:1127–1136. [PubMed: 20116374]
- O'Brien TP, Metallinos DL, Chen H, Shin MK, Tilghman SM. Complementation mapping of skeletal and central nervous system abnormalities in mice of the piebald deletion complex. *Genetics.* 1996; 143:447–461. [PubMed: 8722795]
- Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res.* 1987; 2:595–610. [PubMed: 3455637]
- Pereira RC, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. *Bone.* 2002; 30:685–691. [PubMed: 11996905]
- Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. *Development.* 2006; 133:3231–3244. [PubMed: 16854976]
- Shi Y, Ye K, Wu H, Sun Y, Shi H, Huo K. Human SMAD4 is phosphorylated at Thr9 and Ser138 by interacting with NLK. *Mol Cell Biochem.* 2010; 333:293–298. [PubMed: 19690946]
- Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn MY, Takeyama K, Nakamura T, Mezaki Y, Takezawa S, Yogiashi Y, Kitagawa H, Yamada G, Takada S, Minami Y, Shibuya H, Matsumoto K, Kato S. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. *Nat Cell Biol.* 2007; 9:1273–1285. [PubMed: 17952062]
- Yu HC, Wu TC, Chen MR, Liu SW, Chen JH, Lin KM. Mechanical stretching induces osteoprotegerin in differentiating C2C12 precursor cells through noncanonical Wnt pathways. *J Bone Miner Res.* 2010; 25:1128–1137. [PubMed: 20200998]
- Zanotti S, Canalis E. Notch and the Skeleton. *Mol Cell Biol.* 2010; 30:886–896. [PubMed: 19995916]
- Zanotti S, Canalis E. Nemo-like kinase inhibits osteoblastogenesis by suppressing bone morphogenetic protein and WNT canonical signaling. *J Cell Biochem.* 2012; 113:449–456. [PubMed: 21928348]
- Zanotti S, Canalis E. Notch signaling in skeletal health and disease. *Eur J Endocrinol.* 2013; 168:R95–R103. [PubMed: 23554451]
- Zeng YA, Rahnama M, Wang S, Sosu-Sedzorme W, Verheyen EM. *Drosophila* Nemo antagonizes BMP signaling by phosphorylation of Mad and inhibition of its nuclear accumulation. *Development.* 2007; 134:2061–2071. [PubMed: 17507407]
- Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. *J Biol Chem.* 2002; 277:44005–44012. [PubMed: 12215457]



**Figure 1.** A. Engineering of the *Nlk* conditional allele showing the wild type and *Nlk* targeted allele. In the conditional allele exon 2 is flanked by *loxP* sites upstream a *PGK-neo* selection cassette flanked by *Frt* sites. The *Nlk* targeted allele is shown before and after Flp and Cre recombination for the removal of the neo cassette and excision of exon 2, respectively. B. Cre-dependent recombination of *Nlk<sup>loxP/loxP</sup>* sites following the crossing of *Nlk<sup>loxP/loxP</sup>* mice with *Prx1-Cre*, *Osx-Cre* or *Bglap-Cre* transgenics.



**Figure 2.** Representative  $\mu$ CT of the distal femur (upper panel), cross sectional  $\mu$ CT images of the femoral midshaft (middle panel), and histological sections of the distal femur stained with toluidine blue (lower panel; magnification 40x), of 3 month old male and female *Osx-Cre;Nik<sup>+/+</sup>* and control *Nik<sup>loxP/loxP</sup>* littermates.



**Figure 3.**

Nlk, Opg and Rankl mRNA levels in calvarial extracts from 3 month *Osx-Cre;Nlk<sup>-/-</sup>* mice (black bars) and control *Nlk<sup>loxP/loxP</sup>* littermates (white bars) of both sexes. mRNA levels are expressed as copy number corrected for *Rpl38* and controls normalized to 1. Values are means  $\pm$  SEM; n = 7 – 8. \*Significantly different from control mice,  $p < 0.05$  by unpaired *t* test.

Table 1

Table 1A. Primers used for allele identification by PCR.			
Genotyping			
Allele	Strand	Sequence 5'-3'	Amplicon Size (bp)
<i>Bglap-Cre</i> transgene	Reverse	TGATACAAGGGACATCTTCC	300
	Forward	CAAATAGCCCTGGCAGAT	
<i>Osx-Cre</i> transgene	Reverse	GTGAAACAGCATTGCTGTCCTT	100
	Forward	GCGGTCTGGCAGTAAAACTATC	
<i>Prx1-Cre</i> transgene	Reverse	GTGAAACAGCATTGCTGTCCTT	100
	Forward	GCGGTCTGGCAGTAAAACTATC	
<i>Nlk</i>	Reverse	AAAATCAAATGCCACCAAA	<i>Nlk<sup>loxP</sup></i> = 400 <i>Nlk<sup>WT</sup></i> = 300
	Forward	GTGGTGCACATCAGTCATCC	
<i>Frt</i> and <i>LoxP</i> recombination	Strand	Sequence 5'-3'	Amplicon Size (bp)
Neo Cassette <i>Frt</i> recombination	Reverse	CAAGGGCCAATGATTCCTTA	<i>Neo</i> deleted = 373 <i>Neo</i> present = 507
	Forward	GGCTGTCTGGAACCTCAGAC	
<i>Nlk<sup>loxP</sup></i> recombination	Reverse	CAAGGGCCAATGATTCCTTA	<i>loxP</i> recombination = 669
	Forward	GTGGTGCACATCAGTCATCC	

Table 1B. Primers used for qRT-PCR determinations.			
Gene	Strand	Sequence 5'-3'	GenBank Accession Number*
<i>Nlk</i>	Forward	AGTCCAGCAGCATACTCTTC	NM_008702
	Reverse	GCTGTTGTTGCCAGGGTTT	
<i>Rpl38</i>	Forward	AGAACAAGGATAATGTGAAGTTCAAGGTTT	NM_001048057 NM_001048058 NM_023372
	Reverse	CTGCTTCAGCTTCTCTGCCTTT	
<i>Tnfrsf11b</i> (Opg)	Forward	CAGAAAGGAAATGCAACACATGACAAC	NM_008764
	Reverse	GCCTCTTCACACAGGGTGACATC	
<i>Tnfrsf11</i> (Rank1)	Forward	TATAGAATCCTGAGACTCCATGAAAAC	NM_011613
	Reverse	CCCTGAAAGCCTTGTTTCATCC	

\* GenBank accession number identifies transcript recognized by primer pairs.

**Table 2**

Femoral microarchitecture assessed by  $\mu$ CT of 1 and 3 month old *Prx1-Cre;Nlk<sup>-/-</sup>* conditional null mice and *Nlk<sup>loxP/loxP</sup>* littermate controls.

Males	1 Month		3 Month	
	Control	<i>Nlk<sup>-/-</sup></i>	Control	<i>Nlk<sup>-/-</sup></i>
<i>Femoral Length (mm)</i>	12.2± 0.4	11.6 ± 0.4	15.4 ± 0.2	15.7 ± 0.1
<i>Distal Femur Trabecular Bone</i>				
Bone Volume/Total Volume (%)	5.1± 0.8	4.6 ± 0.9	5.6 ± 0.7	8.0± 1.1
Trabecular Number (1/mm)	4.9± 0.7	3.9 ± 0.4	4.5 ± 0.1	5.1± 0.2*
Trabecular Thickness ( $\mu$ m)	24± 1	24 ± 1	31 ± 1	32± 1
Connectivity Density (1/mm <sup>3</sup> )	182± 61	152 ± 38	135 ± 29	239± 26*
Structure Model Index	2.8± 0.1	2.7 ± 0.1	2.9 ± 0.1	2.6± 0.1
<i>Femoral Midshaft Cortical Bone</i>				
Bone Volume/Total Volume (%)	90.1± 1.2	87.0 ± 1.0	92.1 ± 0.4	91.3± 0.5
Cortical Thickness ( $\mu$ m)	108± 5	88 ± 6	188 ± 5	185± 2
Total Area (mm <sup>2</sup> )	1.4± 0.1	1.5 ± 0.1	1.7 ± 0.1	1.9 ± 0.1
Bone Area (mm <sup>2</sup> )	0.49± 0.02	0.44 ± 0.04	0.89 ± 0.05	0.93 ± 0.02
Periosteal Perimeter (mm)	4.3± 0.1	4.3 ± 0.2	4.6 ± 0.1	4.8 ± 0.1
Endocortical Perimeter (mm)	3.4± 0.1	3.6 ± 0.2	3.2 ± 0.1	3.4 ± 0.1

Females	1 Month		3 Month	
	Control	<i>Nlk<sup>-/-</sup></i>	Control	<i>Nlk<sup>-/-</sup></i>
<i>Femoral Length (mm)</i>	12.0± 0.1	11.9 ± 0.3	16.1 ± 0.1	16.3 ± 0.1
<i>Distal Femur Trabecular Bone</i>				
Bone Volume/Total Volume (%)	3.5± 0.2	4.2 ± 0.2	8.8 ± 0.8	9.7± 1.6
Trabecular Number (1/mm)	3.7± 0.1	3.8 ± 0.1	4.6 ± 0.1	4.5± 0.1
Trabecular Thickness ( $\mu$ m)	24± 0	24 ± 0	37 ± 1	38± 2
Connectivity Density (1/mm <sup>3</sup> )	84± 13	122 ± 16	168 ± 17	188± 25
Structure Model Index	2.8± 0.1	2.7 ± 0.1	2.4 ± 0.1	2.3± 0.2
<i>Femoral Midshaft Cortical Bone</i>				
Bone Volume/Total Volume (%)	88.5± 0.4	88.0 ± 1.6	91.0 ± 0.4	90.0± 0.3
Cortical Thickness ( $\mu$ m)	103± 3	98 ± 6	181 ± 5	169± 6
Total Area (mm <sup>2</sup> )	1.4± 0.1	1.5 ± 0.1	1.7± 0.1	1.8± 0.1
Bone Area (mm <sup>2</sup> )	0.48± 0.01	0.49 ± 0.03	0.87± 0.03	0.85± 0.02
Periosteal Perimeter (mm)	4.2± 0.1	4.3 ± 0.1	4.7± 0.1	4.7± 0.1
Endocortical Perimeter (mm)	3.4± 0.1	3.5 ± 0.1	3.3± 0.1	3.4± 0.1

$\mu$ CT was performed in distal femurs for trabecular bone and midshaft for cortical bone from 1 and 3 month old male and female *Prx1-Cre;Nlk<sup>-/-</sup>* conditional null mice (*Nlk<sup>-/-</sup>*) and control *Nlk<sup>loxP/loxP</sup>* littermates (Control). Values are means ± SEM; n = 3 to 7.

\* Significantly different from controls,  $p < 0.05$  by unpaired *t*-test.



Table 3

Femoral microarchitecture assessed by  $\mu$ CT of 1, 3 and 6 month old *Osx-Cre;Nlk* / conditional null mice and *Nlk<sup>loxP/loxP</sup>* littermate controls.

Males	1 Month		3 Month		6 Month	
	Control	<i>Nlk</i> /	Control	<i>Nlk</i> /	Control	<i>Nlk</i> /
<i>Femoral Length (mm)</i>	12.3±0.1	12.0 ± 0.2	15.5 ± 0.3	15.9 ± 0.2	16.1 ± 0.1	16.0±0.1
<i>Distal Femur Trabecular Bone</i>						
Bone Volume/Total Volume (%)	5.2±0.4	5.2 ± 0.7	5.8 ± 0.6	10.7± 1.8*	7.9 ± 0.9	7.1± 0.9
Trabecular Number (1/mm)	4.3±0.2	4.4 ± 0.2	4.4 ± 0.1	5.4±0.3*	3.6 ± 0.2	4.0± 0.2
Trabecular Thickness (µm)	26± 1	25 ± 1	32 ± 1	34± 2	44 ± 2	36± 2*
Connectivity Density (1/mm <sup>3</sup> )	142± 20	165 ± 58	145 ± 20	327± 65*	101 ± 20	129± 24
Structure Model Index	2.8±0.1	2.8 ± 0.1	2.8 ± 0.1	2.2±0.2*	2.3 ± 0.2	2.3± 0.1
<i>Femoral Midshaft Cortical Bone</i>						
Bone Volume/Total Volume (%)	84.8± 1.1	83.3 ± 0.7	94.1 ± 0.1	94.0±0.2	91.3 ± 0.4	91.6±0.4
Cortical Thickness (µm)	102± 4	93 ± 3	189 ± 4	191± 9	187 ± 5	189± 9
Total Area (mm <sup>2</sup> )	1.3±0.1	1.3 ± 0.1	1.6 ± 0.1	2.0±0.2	2.1 ± 0.2	1.9± 0.1
Bone Area (mm <sup>2</sup> )	0.48± 0.02	0.47 ± 0.03	0.83 ± 0.05	0.97±0.09	1.00 ± 0.07	0.97± 0.05
Periosteal Perimeter (mm)	4.0±0.1	4.0 ± 0.1	4.5 ± 0.1	4.9±0.2	5.1 ± 0.2	4.9± 0.1
Endocortical Perimeter (mm)	3.1±0.1	3.1 ± 0.1	3.2 ± 0.1	3.5±0.1	3.7 ± 0.2	3.4± 0.1
<b>Females</b>						
<i>Femoral Length (mm)</i>	12.3±0.3	12.7 ± 0.2	15.5 ± 0.2	15.6 ± 0.1	16.4 ± 0.2	16.1± 0.1
<i>Distal Femur Trabecular Bone</i>						
Bone Volume/Total Volume (%)	3.8± 0.4	4.1 ± 0.6	4.0 ± 0.8	6.1± 0.3*	3.2 ± 0.5	3.2± 0.6
Trabecular Number (1/mm)	4.0± 0.2	4.0 ± 0.2	3.4 ± 0.2	3.8± 0.1†	2.8 ± 0.1	2.7± 0.1
Trabecular Thickness (µm)	23± 0	23 ± 1	36 ± 1	35± 0	40 ± 3	37± 2
Connectivity Density (1/mm <sup>3</sup> )	77± 16	124 ± 35	56 ± 16	130± 11*	34 ± 7	38± 8
Structure Model Index	2.9± 0.1	2.9 ± 0.1	3.0 ± 0.2	2.5± 0.1*	3.0 ± 0.2	2.8± 0.1

Females	1 Month		3 Month		6 Month	
	Control	<i>Nlk</i> /	Control	<i>Nlk</i> /	Control	<i>Nlk</i> /
<i>Femoral Midshaft Cortical Bone</i>						
Bone Volume/Total Volume (%)	85.1±0.6	85.0±1.2	94.3±0.1	93.6±0.2*	91.8±0.3	91.3±0.3
Cortical Thickness (µm)	103±2	100±5	187±4	171±4*	193±4	187±6
Total Area (mm <sup>2</sup> )	1.4±0.1	1.5±0.1	1.4±0.1	1.5±0.1	1.7±0.1	1.7±0.1
Bone Area (mm <sup>2</sup> )	0.53±0.02	0.53±0.03	0.75±0.02	0.73±0.01	0.87±0.02	0.87±0.02
Periosteal Perimeter (mm)	4.2±0.1	4.3±0.1	4.3±0.1	4.4±0.1	4.6±0.1	4.7±0.1
Endocortical Perimeter (mm)	3.3±0.1	3.4±0.1	3.0±0.1	3.2±0.1*	3.2±0.1	3.2±0.1

µCT was performed in distal femurs for trabecular bone and midshaft for cortical bone from 1, 3 and 6 month old male and female *Oxx-Cre;Nlk* / conditional null mice (*Nlk* / ) and control *Nlk<sup>loxP</sup>/loxP* littermates (Control). Values are means ± SEM; n = 5 to 6.

\* Significantly different from controls,  $p < 0.05$  by unpaired *t*-test.

+  $p < 0.051$ .

**Table 4**Femoral histomorphometry of 3 month old *Osx-Cre;Nlk* / conditional null mice and *Nlk<sup>loxP/loxP</sup>* controls.

<b>Males</b>		
	<b>Control</b>	<b><i>Nlk</i> /</b>
<i>Distal Femur Trabecular Bone</i>		
Bone Volume/Tissue Volume (%)	10.5 ± 1.7	14.1 ± 2.2
Trabecular Number (1/mm)	2.9 ± 0.2	3.4 ± 0.2
Trabecular Thickness (µm)	35 ± 3	40 ± 4
Osteoblast Surface/Bone Surface (%)	9.2 ± 1.3	8.8 ± 1.4
Osteoblasts/Bone Perimeter (1/mm)	11.1 ± 1.6	10.4 ± 1.5
Osteoid Surface/Bone Surface (%)	2.2 ± 0.4	1.0 ± 0.4*
Osteoclast Surface/Bone Surface (%)	9.1 ± 0.8	6.2 ± 0.7*
Osteoclasts/Bone Perimeter (1/mm)	5.7 ± 0.5	3.9 ± 0.4*
Eroded Surface/Bone Surface (%)	15.0 ± 1.2	10.1 ± 1.0*
Mineral Apposition Rate (µm/day)	1.1 ± 0.1	1.0 ± 0.1
Mineralizing Surface/Bone Surface (%)	14.6 ± 1.5	11.9 ± 1.7
Bone Formation Rate (µm <sup>3</sup> /µm <sup>2</sup> /day)	0.17 ± 0.03	0.12 ± 0.03
Adipocytes (mm <sup>2</sup> )	122 ± 19	94 ± 17

<b>Females</b>		
	<b>Control</b>	<b><i>Nlk</i> /</b>
<i>Distal Femur Trabecular Bone</i>		
Bone Volume/Tissue Volume (%)	4.7 ± 0.5	7.3 ± 0.5*
Trabecular Number (1/mm)	1.7 ± 0.1	2.2 ± 0.1*
Trabecular Thickness (µm)	27 ± 1	33 ± 1
Osteoblast Surface/Bone Surface (%)	18.5 ± 1.4	13.5 ± 1.6*
Osteoblasts/Bone Perimeter (1/mm)	19.8 ± 1.3	14.5 ± 1.6*
Osteoid Surface/Bone Surface (%)	4.5 ± 1.0	1.8 ± 0.6*
Osteoclast Surface/Bone Surface (%)	11.7 ± 1.0	9.6 ± 0.7
Osteoclasts/Bone Perimeter (1/mm)	7.6 ± 0.6	6.5 ± 0.5
Eroded Surface/Bone Surface (%)	19.9 ± 1.7	16.9 ± 1.5
Mineral Apposition Rate (µm/day)	1.7 ± 0.1	1.7 ± 0.1
Mineralizing Surface/Bone Surface (%)	15.2 ± 3.9	13.3 ± 1.9
Bone Formation Rate (µm <sup>3</sup> /µm <sup>2</sup> /day)	0.25 ± 0.06	0.23 ± 0.03
Adipocytes (mm <sup>2</sup> )	215 ± 31	213 ± 37

Bone histomorphometry was performed in distal femurs from 3 month old male and female *Osx-Cre;Nlk* / conditional null mice (*Nlk* / ) and control *Nlk<sup>loxP/loxP</sup>* littermates (Control). Values are means ± SEM; n = 6 to 8.

\* Significantly different from controls,  $p < 0.05$  by unpaired  $t$ -test.

Table 5

Femoral microarchitecture assessed by  $\mu$ CT of 1, 3 and 6 month old *Bgap-Cre;Nlk* / conditional null mice and *Nlk<sup>loxP/loxP</sup>* littermate controls.

Males	1 Month		3 Month		6 Month	
	Control	Nlk /	Control	Nlk /	Control	Nlk /
<i>Femoral Length (mm)</i>	12.6±0.1	12.6 ± 0.2	15.5 ± 0.3	15.5 ± 0.1	16.4 ± 0.1	16.6±0.2
<i>Distal Femur Trabecular Bone</i>						
Bone Volume/Total Volume (%)	5.7±0.3	6.3 ± 0.8	7.0 ± 1.2	7.1±1.6	3.8 ± 0.8	4.8±0.8
Trabecular Number (1/mm)	4.8±0.2	4.7 ± 0.3	4.5 ± 0.2	4.5±0.3	3.5 ± 0.2	3.7±0.1
Trabecular Thickness (µm)	25±0	26 ± 1	34 ± 3	33±1	34 ± 2	33±2
Connectivity Density (1/mm <sup>3</sup> )	188± 25	249 ± 70	157 ± 28	155±45	72 ± 19	116±31
Structure Model Index	2.8±0.1	2.8 ± 0.1	2.7 ± 0.1	2.6±0.2	3.0 ± 0.1	2.7±0.1
<i>Femoral Midshaft Cortical Bone</i>						
Bone Volume/Total Volume (%)	87.0±0.5	86.0 ± 0.5	94.0 ± 0.2	93.9±0.1	92.4 ± 0.4	92.3±0.3
Cortical Thickness (µm)	107± 3	103 ± 2	187 ± 8	182± 3	199 ± 0	194±4
Total Area (mm <sup>2</sup> )	1.4±0.1	1.3 ± 0.1	1.7 ± 0.1	1.7±0.1	1.9 ± 0.1	2.0±0.1
Bone Area (mm <sup>2</sup> )	0.51±0.01	0.49 ± 0.02	0.83 ± 0.04	0.80±0.04	0.97 ± 0.04	0.99±0.05
Periosteal Perimeter (mm)	4.2±0.1	4.1 ± 0.1	4.6 ± 0.1	4.6±0.1	4.9 ± 0.1	5.1±0.1
Endocortical Perimeter (mm)	3.3±0.1	3.3 ± 0.1	3.3 ± 0.1	3.3±0.1	3.5 ± 0.1	3.6±0.1
Females	1 Month		3 Month		6 Month	
	Control	Nlk /	Control	Nlk /	Control	Nlk /
<i>Femoral Length (mm)</i>	12.7±0.1	12.8 ± 0.1	15.5 ± 0.2	15.6 ± 0.1	16.4 ± 0.1	16.5±0.2
<i>Distal Femur Trabecular Bone</i>						
Bone Volume/Total Volume (%)	5.2±0.6	4.7 ± 0.5	3.8 ± 0.5	5.4±0.8	2.1 ± 0.4	1.6±0.3
Trabecular Number (1/mm)	4.6±0.2	4.0 ± 0.2	3.6 ± 0.1	3.9±0.2	2.7 ± 0.1	2.3±0.2*
Trabecular Thickness (µm)	24±0	24 ± 0	31 ± 1	34±0*	34 ± 2	41±3*
Connectivity Density (1/mm <sup>3</sup> )	199± 68	147 ± 53	70 ± 16	101± 13	19 ± 7	12± 3
Structure Model Index	2.7±0.1	2.8 ± 0.1	3.0 ± 0.1	2.7±0.1	3.3 ± 0.1	3.4±0.2
<i>Femoral Midshaft Cortical Bone</i>						

Females	1 Month		3 Month		6 Month	
	Control	<i>Nlk</i> /	Control	<i>Nlk</i> /	Control	<i>Nlk</i> /
Bone Volume/Total Volume (%)	88.0±0.3	87.0 ± 0.5	93.8 ± 0.1	93.8±0.1	92.3 ± 0.6	92.5±0.2
Cortical Thickness (µm)	110±3	109 ± 4	176 ± 2	179± 3	202 ± 4	198± 5
Total Area (mm <sup>2</sup> )	1.4± 0.1	1.4± 0.1	1.6 ± 0.1	1.7± 0.1	1.8± 0.1	1.8± 0.1
Bone Area (mm <sup>2</sup> )	0.50±0.03	0.53± 0.02	0.77 ± 0.02	0.79± 0.02	0.89± 0.03	0.91± 0.03
Periosteal Perimeter (mm)	4.2± 0.1	4.2± 0.1	4.5 ± 0.1	4.6± 0.1	4.7± 0.1	4.7± 0.1
Endocortical Perimeter (mm)	3.4± 0.1	3.3± 0.1	3.3 ± 0.1	3.3± 0.1	3.3± 0.1	3.3± 0.1

µCT was performed in distal femurs for trabecular bone and midshaft for cortical bone from 1, 3 and 6 month old male and female *Bglap-Cre;Nlk* / conditional null mice (*Nlk* / ) and control *Nlk<sup>loxP/loxP</sup>* littermates (Control). Values are means ± SEM; n = 3 to 6.

\* Significantly different from controls,  $p < 0.05$  by unpaired *t*-test.